Tempest Therapeutics (TPST)
(Delayed Data from NSDQ)
$2.22 USD
0.00 (0.00%)
Updated Jul 16, 2024 04:00 PM ET
Pre-Market: $2.21 -0.01 (-0.45%) 9:06 AM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TPST 2.22 0.00(0.00%)
Will TPST be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TPST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TPST
Tempest (TPST) Up as First-Line Liver Cancer Study Meets Goals
All You Need to Know About Tempest Therapeutics, Inc. (TPST) Rating Upgrade to Buy
TPST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tempest Therapeutics, Inc. (TPST) Upgraded to Buy: What Does It Mean for the Stock?
Bears are Losing Control Over Tempest Therapeutics, Inc. (TPST), Here's Why It's a 'Buy' Now
Other News for TPST
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT), BioNTech SE (BNTX) and Tempest Therapeutics (TPST)
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
12 Health Care Stocks Moving In Thursday's Intraday Session
Gold Rises 1%; Accenture Shares Surge After Q3 Results
Tempest falls after new trial data for liver cancer therapy